Preclinical Evaluation of a New Series of Albumin-Binding
albumin
linker
prostate cancer
prostate-specific membrane antigen
radiopharmaceutical therapy
Journal
Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009
Informations de publication
Date de publication:
21 Aug 2023
21 Aug 2023
Historique:
received:
17
06
2023
revised:
12
08
2023
accepted:
17
08
2023
medline:
28
8
2023
pubmed:
26
8
2023
entrez:
26
8
2023
Statut:
epublish
Résumé
Prostate-specific membrane antigen (PSMA)-based low-molecular-weight agents using beta(β)-particle-emitting radiopharmaceuticals is a new treatment paradigm for patients with metastatic castration-resistant prostate cancer. Although results have been encouraging, there is a need to improve the tumor residence time of current PSMA-based radiotherapeutics. Albumin-binding moieties have been used strategically to enhance the tumor uptake and retention of existing PSMA-based investigational agents. Previously, we developed a series of PSMA-based, β-particle-emitting, low-molecular-weight compounds. From this series,
Identifiants
pubmed: 37630410
pii: molecules28166158
doi: 10.3390/molecules28166158
pmc: PMC10459686
pii:
doi:
Substances chimiques
Ligands
0
Albumins
0
Butyric Acid
107-92-6
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIH HHS
ID : EB024495
Pays : United States
Organisme : NIH HHS
ID : CA267374
Pays : United States
Organisme : NIH HHS
ID : CA184228
Pays : United States
Références
Eur J Nucl Med Mol Imaging. 2019 Nov;46(12):2545-2557
pubmed: 31399803
J Med Chem. 2008 Aug 14;51(15):4504-17
pubmed: 18637669
Mol Imaging Biol. 2020 Apr;22(2):274-284
pubmed: 31321650
Lancet. 2021 Sep 18;398(10305):1075-1090
pubmed: 34370973
Mamm Genome. 2001 Feb;12(2):117-23
pubmed: 11210180
J Nucl Med. 2019 May;60(5):656-663
pubmed: 30552199
Theranostics. 2020 Jan 1;10(4):1678-1693
pubmed: 32042329
Lancet. 2021 Feb 27;397(10276):797-804
pubmed: 33581798
Cancer Res. 1999 Jul 1;59(13):3192-8
pubmed: 10397265
Biomolecules. 2022 Mar 05;12(3):
pubmed: 35327597
J Nucl Med. 2019 Mar;60(3):400-406
pubmed: 30237212
Prostate. 2009 Jul 1;69(10):1128-41
pubmed: 19367568
Biochem Pharmacol. 1973 Dec 1;22(23):3099-108
pubmed: 4202581
Theranostics. 2017 Apr 27;7(7):1928-1939
pubmed: 28638478
J Nucl Med. 2021 Apr;62(4):521-527
pubmed: 32859704
J Nucl Med. 2022 Feb;63(2):259-267
pubmed: 34088772
Theranostics. 2022 Aug 21;12(14):6179-6188
pubmed: 36168623
N Engl J Med. 2021 Sep 16;385(12):1091-1103
pubmed: 34161051
J Nucl Med. 2023 Apr;64(4):611-617
pubmed: 36328486
Eur J Nucl Med Mol Imaging. 2018 Oct;45(11):1841-1851
pubmed: 29623376
Nat Rev Dis Primers. 2021 Feb 4;7(1):9
pubmed: 33542230
Eur J Nucl Med Mol Imaging. 2021 Mar;48(3):893-903
pubmed: 32949253
Cancers (Basel). 2022 Nov 17;14(22):
pubmed: 36428743
Theranostics. 2022 Oct 17;12(17):7203-7215
pubmed: 36438496
J Nucl Med. 2020 Dec;61(12):1772-1778
pubmed: 32358086
J Med Chem. 2023 Jun 22;66(12):8043-8053
pubmed: 37285471
J Nucl Med. 2021 Jul 1;62(7):980-988
pubmed: 33246975
J Nucl Med. 2021 Aug 12;:
pubmed: 34385339
Nat Protoc. 2006;1(5):2315-9
pubmed: 17406473
Br J Cancer. 1995 Sep;72(3):583-8
pubmed: 7669565
Mol Pharm. 2018 Mar 5;15(3):934-946
pubmed: 29400475
J Nucl Med. 2017 Sep;58(Suppl 2):17S-26S
pubmed: 28864607
Eur J Nucl Med Mol Imaging. 2022 Sep;49(11):3639-3650
pubmed: 35635566
Medchemcomm. 2019 Jun 6;10(7):1068-1081
pubmed: 31391879
J Med Chem. 2010 Jul 22;53(14):5333-41
pubmed: 20568777
Molecules. 2023 May 11;28(10):
pubmed: 37241763
Angew Chem Int Ed Engl. 2011 Sep 19;50(39):9167-70
pubmed: 21861274
Oncotarget. 2011 Dec;2(12):1244-53
pubmed: 22207391
Urol Oncol. 1995 Jan-Feb;1(1):18-28
pubmed: 21224086
CA Cancer J Clin. 2023 Jan;73(1):17-48
pubmed: 36633525
Clin Cancer Res. 1997 Jan;3(1):81-5
pubmed: 9815541
Eur J Nucl Med Mol Imaging. 2022 Jan;49(2):470-480
pubmed: 34402925
J Nucl Med. 2020 Jan;61(1):80-88
pubmed: 31253744
Mol Pharm. 2020 Jun 1;17(6):2044-2053
pubmed: 32383887
Bioconjug Chem. 2019 Mar 20;30(3):487-502
pubmed: 30616340
J Neurochem. 2004 May;89(4):876-85
pubmed: 15140187